NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund
Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route.
You may also be interested in...
Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.
Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.